Pharmacological management of post-traumatic seizures in a South African paediatric intensive care unit

N Yachad1, K D Naidoo2

  • 1Department of Paediatrics, University of the Witwatersrand, Johannesburg, South Africa.

Insights

Post-traumatic seizures (PTS) are common in children with severe traumatic brain injury (TBI). Management of PTS varies, highlighting the need for further research to optimize care and minimize secondary brain injury in pediatric intensive care units.

Area of Science:

  • Pediatric Intensive Care
  • Neurology
  • Trauma Surgery

Background:

  • Traumatic brain injury (TBI) is a significant cause of pediatric intensive care unit (PICU) admissions in South Africa.
  • Post-traumatic seizures (PTS) are a critical complication of TBI, necessitating effective prevention and management to avoid secondary brain injury.

Purpose of the Study:

  • To characterize the demographics of pediatric patients admitted to a South African PICU following TBI.
  • To describe the incidence and clinical features of post-traumatic seizures (PTS) in this population.
  • To evaluate the prophylactic and therapeutic strategies employed for PTS management within the PICU.

Main Methods:

  • A retrospective chart review was conducted over three years (July 2015 - June 2018) at the PICU of Chris Hani Baragwanath Academic Hospital.
  • Data collected included patient demographics, TBI characteristics, seizure occurrence, and anti-epileptic drug (AED) management.
  • Analysis focused on the incidence of early and late PTS, seizure types, and treatment outcomes.

Main Results:

  • Severe TBI was the primary reason for PICU admission, predominantly due to mechanical injury (89%).
  • Overall PTS incidence was 43%, with higher rates in younger children (<2 years).
  • Significant variability was observed in AED prophylaxis and maintenance therapy, with only 56% of drug levels within the target range.

Conclusions:

  • Post-traumatic seizures (PTS) represent a frequent complication of severe TBI in children.
  • Current practices for PTS prophylaxis and maintenance therapy show considerable variation, including agent choice, dosage, and drug monitoring.
  • Further high-level research is essential to establish evidence-based guidelines for optimizing PTS management in pediatric TBI patients.
Abstract

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
70
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
833
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
269
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
426
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
591
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
574